Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Other Non-Current Liabilities: 2022-2024

Historic Other Non-Current Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 1 years, with Sep 2024 value amounting to $18.8 million.

  • NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities was N/A to $18.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $18.8 million, marking a year-over-year change of. This contributed to the annual value of $7.8 million for FY2023, which is 3.54% up from last year.
  • As of Q3 2024, NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities stood at $18.8 million, which was up 40.42% from $13.4 million recorded in Q2 2024.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities peaked at $18.8 million during Q3 2024, and registered a low of $7,553 during Q2 2023.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities had a median value of $10.6 million in 2023 and averaged $10.7 million.
  • Data for NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities shows a peak YoY soared of 177,233.51% (in 2024) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities (Quarterly) stood at $7.5 million in 2022, then increased by 3.54% to $7.8 million in 2023, then skyrocketed by 177,233.51% to $18.8 million in 2024.
  • Its Other Non-Current Liabilities stands at $18.8 million for Q3 2024, versus $13.4 million for Q2 2024 and $16.5 million for Q1 2024.